ABSTRACT
Objective To observe the curative effect and side effect ofdifferent dosage of flurbiprofen applied in refractory renal colic cases.Methods Two hundred refractory renal cohc cases were randomly divided into group A and group B,each group was 100 cases.Group A were apphed 100 mg flurbiprofen injection,group B were applied 50 mg flurbiprofen injection.Observed the time of the colic pain reheved,the curative effect and side effect Results The total effective rate of group A and group Bwere 99%(99/100)and 91%(911100)respectively,there was significant difference between two groups(P<0.05).In the time to relieve of group A and group B were(8.3±5.7)min and(13.2±9.1)min respectively,there Was significant difference between two groups(P<0.05).Analgesia continuous time of group A and group B were(19.3 ±3.2)h and(14.5 4±5.1)h respectively,there was no significant difference between two groups(P>0.05).And side effect was no significant difference between two groups.Conclusion The curative effect of 100mg flurbiprofen injection applied to the refractory renal colic cases is very outstanding,the time to relieve is very shod but side effect dose not increase.
ABSTRACT
Background and purpose:The greastest diameter of cervical cancer with stage Ⅰ_(b2) disease was more than 4 cm in diameter. surgery as the fi rst priority was diffi cult in these patients, bleeding was the most frequent adverse effect. This article studied the effect of the cervical cancer with stage Ⅰ_(b2) disease underwent neoadjuvant chemotherapy with gemcitabin plus cisplatinum(DDP). Methods:23 cases (A groups) stage Ⅰ_(b2) cervical cancer were treated with gemcitabin 1.5 g/m2 iv infusion at d1, plus cisplatinum(DDP) 20 mg/m2 iv infusion at d1-3. The interval between the two cycles was two weeks.19 cases (B groups) were treated with cisplatinum(DDP) 20 mg/m2 iv infusion at d1-3,plus VCR 1.5 g/m2 iv infusion at d1, and BLM 10 mg/m2 im at d1-3, The interval between the two cycles was three weeks. The assessment for clinical effect and side effect were conducted for the patients with completion of at least two cycles of chemotherapy. Results:42 cases were enrolled in this trial. There was signifi cant(P=0.004) difference between the two groups with the shrinkage of the greatest diameter after neoadjuvant chemotherapy. The main toxicities were myelosuppression. There was signifi cant (P
ABSTRACT
Background and purpose:The clear-cell cancer ovarian cancer have worse prognosis than the other ovarian cancer.The patient's survival rate of the clear-cell ovarian cancer has been analyzed in this article in order to study the effect of the treatment with CAPcytoxan(CTX),cisplatinum(DDP),epiadriamycin(E-ADM)plus mitomycin(MMC).Methods:33 cases(group A)with clear-cell ovarian cancer between Jan.1th 1999 and Dec.31th 1999 were compared to 37 cases(B group)with other pathological ovarian cancer.All cases underwent the tumor reductive surgery and been capable of remain the residual tumor size less than 1 cm.Patients in the two groups all underwent CAP based chemotherapy,and patients in group A with additional MMC chemotherapy at the same time.Group A had been compared with the clear-cell ovarian cancer with the CAP protocol(group C,stage Ⅰ/Ⅱ 15 cases,stage Ⅲ/Ⅳ 9 cases).Results:There was significant statistical different value of the CA125 in stage Ⅰ/Ⅱ before operation and no significant statistical difference for stage Ⅲ/Ⅳ between the two groups.There were significant decrease in the CA125 value for the stage Ⅰ/Ⅱ and no significant decrease for stage Ⅲ/Ⅳ between two groups after three and six courses chemotherapy.There were 11(33.33%)cases developed with endometriosis and 7(21.21%)with deep venous thrombosis(DVT),however the DVT had no direct correlation to the survival rate.The average survival time for stages Ⅰ/Ⅱ in group A and B was(38.3?2.4),and(38.3?2.7)months,compared to(20?3)and(34?4)months in stage Ⅲ/Ⅳ,respectively.There was no significant statistical difference(P=0.471)in four-year survival rate between groups A and B with stage Ⅰ/Ⅱ and there was significant statistical difference(P
ABSTRACT
Objective To evaluate the curative effect of transurethral electrosection for the treatment of bladder neck sclerosis in senile patients. Methods Clinical data of 36 aged patients with bladder neck sclerosis treated by transurethral electrosection in this hospital from February to September, 2000, were reviewed. The curative effect was evaluated according to the improvement of dysuria, residual urine volume (RUV) and Qmax before and after the surgery. Results Follow-up for 3～18 months (mean, 7 months) in 30 patients showed an effective rate of 86.7% (26/30) and no severe complications. Conclusions Transurethral electrosection is an effective alternative for bladder neck sclerosis in senile men.
ABSTRACT
Purpose:To study the intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer. Methods:The 88 patients of ovarian cancer after cytoreductive surgery were divided into two groups A and B. A group(45 cases) received intraperitonal chemotherapy three times once a week with DDP and 5-FU plus either the MMC or AT-1258, then intravenous chemotherapy, stages Ⅰ/Ⅱ 21 cases(23.86%),stages Ⅲ/Ⅳ 24 cases(27.27%). B groups were given intravenous chemotherapy with CAP protocol once every three weeks,stage Ⅰ/Ⅱ 24 cases(27.27%),stages Ⅲ/Ⅳ 19 cases(21.59%).Results:After three or six courses of chemotherapy there was significant decrease in CA125 both Ⅰ/Ⅱ and Ⅲ/Ⅳ in A and B groups . After three courses of chemotherapy there were 34 cases((38.64%))of A groups and 19 cases(21.59%)of the B groups with CA12535 u/ml(35 cases) who were given three courses of chemotherapy after entire treatment. A and B groups in the Ⅰ/Ⅱ stages showed average survival time (35.05?0.54),(32.38?1.19) months,and in the Ⅲ/Ⅳ stages showed average survival time (31.33?1.41),(28.26?1.88) months.There was no significance (P=0.156) with three year survival rate between A and B groups in the Ⅰ/Ⅱ stages with Log Rank test. There was no significance (P=0.08) in three-year survival rate between A and B groups in the Ⅲ/Ⅳ stages with Log Rank test. There was significance in three-year survival rate between A and B with intraperitonal fluid.Conclusions:The intraperitonal chemotherapy combined with intravenous chemotherapy after surgery for the treatment of ovarian cancer could marketly decrease CA125 than intravenous chemotherapy after three or six courses. Three-year survival ratewas significantly different between CA125 35 u/ml(35 cases) when they were given three courses of chemotherapy after entire treatment. Although the intraperitonal chemotherapy after surgery for the treatment of ovarian cancer had no significant difference between A and B groups in Ⅰ/Ⅱ and Ⅲ/Ⅳ stages with three-year survival rate , it appears longer survival time . There is significant difference with three-year survival between A and B with intraperitonal fluid. The intraperitional chemotherapy combined with intravenous chemotherapy after surgery can be used for the ovarian cancer with intraperitonal fluid and metastases.